A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary) ; Iodine radioactive
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 22 Jan 2019 Status changed from not yet recruiting to recruiting.
- 22 Jan 2019 Planned End Date changed from 30 Apr 2021 to 31 Jan 2021.
- 22 Jan 2019 Planned primary completion date changed from 30 Apr 2020 to 31 Jan 2021.